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PR: progesterone receptor 
TMA: tissue micro array 
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TURP: transurethral resection of the prostate 
TRUS transrectal ultra sound 
IHC: immunohistochemistry 
WST: water soluble tetrazolium salts 
AR: androgen receptor 
IQR: interquartile range 
siRNA: small interfering ribonucleic acid 
IFN: interferon 
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Abstract 
STAT1 loss has previously been implicated in cell line studies to modify prostate 
cancer cell growth and survival, however the clinical significance of this has not been 
previously been established.  This study investigated if STAT1 loss was associated 
with patient outcome measures and the phenotypic consequence of STAT1 silencing.  
STAT1 expression was assessed in two patient cohorts with localised (n=78) and 
advanced prostate cancer at initial diagnosis (n=39) by immunohistochemistry (IHC). 
Impact of STAT1 silencing on prostate cancer cells lines was assessed using Cell 
Death detection ELISA, TLDA gene signature apoptosis arrays, WST-1 assay, 
xCELLigence system, clonogenic assay and wound healing assay.  In the localised 
patient cohort, low expression of STAT1 was associated with shorter time to disease 
recurrence (3.8 vs 7.3 years, p=0.02) and disease specific survival (6.6 vs 9.3 years, 
p=0.05).  In the advanced patient cohort, low expression was associated with shorter 
time to disease recurrence (2.0 vs 3.9 years, p=0.001). When STAT1 was silenced in 
PC3 cells (AR negative) and LNCaP cells (AR positive) silencing did not influence 
levels of apoptosis in either cell line and had little effect on cell viability in the LNCaP 
cells.  In contrast, STAT1 silencing in the PC3 cells resulted in a pronounced 
increase in cell viability (WST-1 assay: mock silenced vs STAT1 silenced, p<0.001), 
clonagenicity (clonogenic assay: mock silenced vs STAT1 silenced, p<0.001) and 
migration (wound healing: mock silenced vs STAT1 silenced, p<0.001).  In 
conclusion, loss of STAT1 may promote prostate cancer recurrence in AR negative 
patients via increasing cell viability.  
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Introduction 
Prostate cancer is a major cause of death in the developed world and is the most 
common cancer amongst men in the UK. Treatment options vary depending on 
grade and staging of patients. For patients with localised prostate cancer, active 
surveillance, radical prostatectomy or radiotherapy may be offered, but within this 
patient group a sub cohort will develop a subsequent recurrence and require further 
intervention [1]. For patients diagnosed with advanced disease, hormone therapy is 
normally the first choice of treatment with the majority of these patients eventually 
recurring with castrate resistant disease [2].  Therefore a major challenge facing 
today’s urologists is predicting which patients are most likely to recur and what 
therapeutic strategy to employ when they do.  In order to identify biomarkers and 
novel therapeutic options for these patients, further understanding of the pathways 
associated with promoting prostate cancer recurrence is required. 
Deregulation of the signal transducers and activators of transcription factors (STAT) 
along with the negative feedback regulators of the Janus-activated kinase (JAK), 
such as members of the SOCS family have been implicated in prostate cancer cell 
growth and survival [3, 4]. STAT members, a group of seven cytoplasmic proteins, 
act as transcription factors to elicit their effects via control of transcriptional 
expression of multiple genes. Aberrant activation of some STAT members, in 
particular STAT3 and STAT5, have been found in a large number of human tumours, 
acting as pro-survival signals for tumour cells via tight regulation of cell cycle 
progression, cellular transformation, and prevention of apoptosis [5, 6].  
Contrary to the function of other family members’ in cancer development, STAT1 is 
believed to act as a tumour suppressor by playing an important role in growth 
progression and apoptosis. In early studies of the role of STAT1 in cancer, it was 
observed that STAT1−/− mice formed significantly more carcinogen-induced 
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sarcomas than wild type mice [7, 8].  Recently, it was demonstrated in a subset of 
patients with ER±+/PR+ breast cancer, that STAT1 expression is lost or significantly 
reduced in the neoplastic cells compared to normal breast epithelium [9]. Moreover, 
female mice lacking longitudinal expression of STAT1, spontaneously developed 
mammary gland cancers of the luminal subtype [9]. Numerous in vitro studies have 
also suggested that STAT1 may function as a tumour suppressor by regulating the 
expression of caspases such as caspase 1, 2, 3, and 7 [10, 11] upregulating p27Kip1 
expression [12] or interacting with p53 or BRCA1 [13, 14].  Paradoxically, STAT1 
accumulation and hyper-activation has also been observed in multiple types of 
cancers, offering a survival advantage to these tumours. Elevated levels of STAT1 in 
squamous cell carcinoma cell lines have been linked to acquisition of resistance to 
radiation or chemotherapy treatment [15].  Furthermore, STAT1 along with clusterin 
protein expression was induced by docetaxel treatment in prostate cancer cells, 
DU145 and overexpressed in a docetaxel-resistant cell line (DU145-DR)[16].  
Therefore, STAT1 expression might be a double-edged sword that functions to either 
suppress or promote cancer development depending on the tissue or cellular context.  
The current study was designed to investigate if STAT1 expression was associated 
with recurrence or patient survival in prostate cancer specimens at initial diagnosis. 
 
Materials and Methods 
Patient cohort.  Cohort 1 contained 78 patients with localised prostate cancer at 
initial diagnosis from Greater Glasgow and Clyde NHS Trust, all of whom were 
diagnosed between 1993 and 2002. Ethical approval was obtained from the West of 
Scotland Research Ethics Committee (05/S0704/94). Each patient in cohort 1 was 
required to have hormone naïve prostate tissue samples available to provide 
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sufficient material for construction of a tissue micro array (TMA).  These patients 
were identified retrospectively and samples were retrieved from archived stored 
specimens. Protein expression in cancer tissue was assessed using TMAs. TMAs 
were constructed using 0.6mm2 cancer tissue cores taken from representative areas 
of tumour from each patient, as identified by a pathologist. All TMA blocks were 
constructed in triplicate, to account for intra-tumour disease heterogeneity. 5µm thick 
sections were used in all experiments. 
Cohort 2 contained 39 patients with advanced prostate cancer at initial diagnosis 
from Greater Glasgow NHS Trust, all of who were diagnosed between 1984 and 
2000. Ethical approval was obtained from West of Scotland Research Ethics 
Committee (98UR004).  Each patient was diagnosed with advanced prostate cancer 
and had tissue available for analysis.  Each patient was observed to respond to 
maximum androgen blockade (androgen deprivation therapy and LHRH agonists) 
and response was defined as a fall in PSA levels of at least 50%.  Tissue was 
obtained from patients by TRUS-guided biopsy or TURP, TMA was constructed (as 
described above) from the TURP specimens but full sections were used for the 
TRUS specimens. These patients were identified retrospectively and samples were 
retrieved from archived stored specimens.  All tumours had patient identification 
removed, and the clinical information database was anonymised.  
Immunohistochemistry (IHC). Tissue sections were dewaxed in xylene and 
rehydrated in a series of graded alcohol. Antigen retrieval was performed under 
pressure for 5 min in Tris-EDTA buffer (pH 8.0). Endogenous peroxidase was 
blocked in 3% hydrogen peroxide for 10 min and non specific binding blocked using 
5% horse serum in tris buffered saline. Incubation with primary STAT1 antibody was 
carried out in a humidified chamber overnight at 4°C (1:200, Cell Signaling 9175, 
UK). Tissue was then incubated in Envision solution (DAKO UK) for 30 min and 
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developed by application of 3,32-diaminobenzidine as a chromogen (DAKO UK). 
Sections were counterstained with hematoxylin, dehydrated through graded alcohol 
and xylene, and mounted in DPX. Prostate tissue was included as positive control 
and an isotype-matched antibody was used on prostate samples to provide a 
negative control. Specificity of the antibody was confirmed by a single band of 87 
kDa on western blotting in cell lysates of PC3 cells treated with mock siRNA or 
siRNA targeting STAT1 (Dharmacon, ThermoScientific, UK; Figure 1A) and positive 
IHC staining was blocked by a peptide specific for the STAT1 antigen (Cell Signaling, 
UK; Figure 1B). AR expression was already available for these cohorts from previous 
studies [17, 18] 
Scoring method. Protein expression levels were assessed blindly by two 
independent observers using a weighted histoscore method also known as the H-
score at magnification ×400. Each cellular location (membrane, cytoplasm, and 
nuclei) was scored separately. The weighted histoscore method assesses the 
staining intensity and the percentage of cells stained with that intensity within the full 
sample. It is calculated by (1 × % cells staining weakly positive) + (2 × % cells 
staining moderately positive) + (3 × % cells staining strongly positive). This provides 
a semi-quantitative classification of staining intensity, with the maximum score 300 (if 
100% of cells stain strongly positive) and minimum score 0 (if 100% of cells are 
negative) [19].  
Cell Culture and Reagents. Prostate cancer cells; LNCaP and PC3 were obtained 
from American Type Culture Collection (ATCC, LGC Standards, UK).  
Transient transfection. LNCaP and PC3 cells were plated in 6-well plates at 
concentration of 2x105 cells/well. At  70% confluent they were transfected with 80nM 
siRNA STAT1 (Dharmacon, ThermoScientific, UK) or 80nM non-targeting of human 
genome control siRNA (Dharmacon, ThermoScientific, UK) or sterile 1x siRNA buffer 
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(control; Dharmacon, ThermoScientific, UK) using Lipofectamine RNAiMAX 
(Invitrogen, UK) as per manufacturers instructions. Best knockdown was observed at 
72h post transfection as assessed by western blotting (Figure 1C).  
Western Blot analysis. Changes observed at the protein level in prostate cancer 
cell lines were assessed by western blotting as previously described [20]. The PVDF 
membranes were probed with primary antibodies STAT1 (1:3000; Cell Signaling 
9175, UK) and STAT3 (1:5000; Cell Signaling 9132, UK). Following visualisation with 
ECL plus (Amersham, UK) membranes were stripped and re-blotted with ² -tubulin 
(Abcam 21058, UK) to ensure equal protein loading. 
Cell Death Detection ELISA Plus. 24h after transient transfection, LNCaP and PC3 
cells were trypsinised and plated at 3 x 104 cells/mL in quadruplicates for untreated 
cells, cells transfected with control siRNA, and cells transfected with siRNA STAT1 in 
96-well plates. Cell Death Detection ELISA Plus kits (Roche Applied Science, UK) 
were used to measured apoptosis at the 72 hour time point by quantifying histone-
DNA complexes generated after inhibitor treatment, as per the manufacturer’s 
protocol.  HRP cleavage of ABTS substrate was measured by absorbance at 405nm.  
Taqman low density arrays. 72 hours following transfection, RNA was extracted 
using Trizol (Invitrogen, UK) as per manufacturer’s instructions. Preparation of cDNA 
and RT-PCR were performed using TaqMan RT-PCR methodology and reagents 
(Perkin-Elmer Applied Biosystems). 
384 TLDA gene signature apoptosis arrays containing 93 genes related to apoptosis 
and 3 candidate endogenous controls were employed to determine if STAT1 
silencing induced change in expression of apoptotic genes. Each sample from 3 
independent silencing experiments on PC3 cells was run in duplicate.  All results 
were analysed simultaneously by RQ Manager Software (ABI, UK) and the threshold 
  S Hatziieremia et al. 
 9 
cycle (Ct) values of the genes of interest were calibrated against 18S Ct (• Ct). 
Results are presented in fold change in the target gene relative to 18S endogenous 
control using the 2-” (” CT) method. 
Cell Viability. 24 hours after transient transfection, LNCaP and PC3 cells were 
trypsinised and plated at 3 x 104 cells/mL in quadruplicates for untreated cells, cells 
transfected with control siRNA, and cells transfected with siRNA STAT1 in 96-well 
plates.  Proliferation of the cells was assessed 72 hours following transfection by 
WST-1 assay as previously described by Tatarov et al. [20].  In brief, cell viability was 
measured by mitochondrial dehydrogenase induced cleavage of water soluble 
tetrazolium salt, via incubation with WST-1 for 2 hours at 37ºC with 5% CO2 in air 
(Roche Applied Science, UK).  Absorbance was then measured at 450nm. 
Furthermore, cells were also plated at 3 x 104 cells/mL in octuplicates in E-Plate 
VIEW96 (Roche, UK) and their viability and proliferation was measured in real-time 
using the xCELLigence system (Roche,UK) as per manufacturer’s instructions over 
144 hours post-transfection.   
Clonogenics assay. 24 hours after transient transfection in 6-well plates, PC3 cells 
were trypsinised and plated at 400 cells/plate in triplicate plates for untreated cells, 
cells transfected with control siRNA, and cells transfected with siRNA STAT1 in 
60mm Nunclon dishes. Following a 10 day incubation in the dishes, PC3 cells were 
washed with ice-cold PBS and fixed with 3mL of methanol for 10 min. Methanol was 
aspirated off and dishes were left to dry for 20 min.  Colonies were stained with 
Crystal Violet solution for 10 min followed by a washing step with water. Colonies 
were counted in each dish and presented as surviving fraction (mean siRNA STAT1 
transfected colonies divided by mean control). 
  S Hatziieremia et al. 
 10 
Cell migration assay.  Wound-healing assay was carried out to investigate the 
ability of PC3 cells to migrate into a denuded area after being transfected with siRNA 
for STAT1. Wounds were made using a fine pipette tip through the cell monolayer 
(three wounds per each well) of PC3 cells 48 hours post transfection with siRNA 
STAT1 in 6-well plates. The medium was then replaced with standard medium prior 
to assessing the wound closure using a Zeiss Axiovert S100 microscope at ×20 
magnification. The assay was done over 20 hours with images taken from four fields 
per each well at 0, 4, 10, 16 and 20 hours. Closure of wound was assessed by 
measurement of the distance between the edges of the wound at each time point 
using ImageJ software.  
Statistical Analysis. Statistical analysis was done using SPSS statistical package 
(version 19.0) and GraphPad Prism4. Survival analysis including time to disease 
recurrence and disease specific survival was conducted using the Kaplan-Meier 
method and curves were compared with the log-rank test. Multi variate analysis was 
performed using the Cox Regression model. In vitro experiments were analysed 
using one-way Anova and are expressed as mean ± s.e.m or % control mean (mean 
of treatment divided by mean of control x100).  
 
Results 
STAT1 expression is associated with recurrence.  To determine the expression 
levels of STAT1 in earlier and more advanced stages of prostate cancer, two 
different patient cohorts were utilised. For the expression of STAT1 in earlier stages 
of the disease, TMAs of paraffin embedded samples from 78 patients with localised 
disease were utilised (cohort 1). While to determine the expression of STAT1 in 
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patients with advanced prostate cancer a cohort of 39 patients was utilised (cohort 
2).  
Patient characteristics for cohort 1 can be seen in Table 1. Briefly, at diagnosis the 
median age was 71, Gleason grade was 7 and PSA level was 19•ng/mL.  Data for 
disease recurrence was available for 63 patients of which 40 relapsed, median 
disease recurrence time was 2.99 years.  At last follow-up 18 patients developed 
metastases, 17 patients were still alive, 42 had died of their disease and 19 died of 
inter-current disease.  Median follow up was 10.5 years.  Ki67 proliferation index and 
AR expression were already available for this cohort and had median histoscore of 3 
and 67.67 units, respectively. 
STAT1 expression was assessed in all specimens available in both stromal and 
tumour cells (Figure 2A). In the tumour cells median membrane STAT1 histoscore 
was 50 units (IQR: 10.8-86.7), median cytoplasmic STAT1 histoscore was 85 units 
(IQR: 50-127.5), median nuclear STAT1 histoscore was 35 units (IQR: 6.7-65.0).  In 
the stromal cells only nuclear expression was observed with a median expression of 
3 units (IQR: 0-15). Specimens were divided in to those with low expression (< lower 
quartile) or high expression (> lower quartile) and Kaplan-Meier curves constructed 
to assess if expression was associated with time to disease recurrence (recurrence) 
or disease specific survival.  Stromal STAT1 expression, tumour cytoplasmic STAT1 
expression and tumour nuclear STAT1 expression were not associated with time to 
disease recurrence or disease specific survival. However, membrane STAT1 
expression in the tumour cells was significantly associated with time to disease 
recurrence (p= 0.02; Figure 2B).  Those patients with high membrane STAT1 
expression had a mean time to disease recurrence of 7.3 years (IQR: 5.5-9.1) 
compared to 3.8 years (IQR: 2.2-5.3) for those with low expression.   Membrane 
STAT1 expression in the tumour cells was also significantly associated with disease 
  S Hatziieremia et al. 
 12 
specific survival (p=0.05) (Figure 2C). Those patients with high membrane STAT1 
expression had a mean time to death (disease specific survival) of 9.3 years (IQR: 
7.8-10.9) compared to 6.6 years (IQR: 4.6-8.6) for those with low expression.  In 
addition, membrane STAT1 expression was inversely associated with recurrence 
(p=0.019) and ki67 proliferation index as assessed by chi square test (p=0.004).   
STAT1 expression was also assessed in the second patient cohort with advanced 
disease at initial diagnosis (table 1).  Briefly, at diagnosis the median age was 70, 
Gleason grade was 8 and PSA level was 41•ng•ml−1.  All patients had disease 
recurrence; median disease recurrence time was 2.64 years.  At diagnosis 25 
patients had locally advanced disease and 14 patients had metastatic disease, 
during follow-up a further 6 patients developed metastases.  No patients were alive at 
last follow up, 29 died of their disease and 10 died of inter-current disease.  Ki67 
proliferation index and AR expression was already available for this cohort, and had 
a median histoscore of 1.5 and 100 units, respectively.  
STAT1 expression was observed in the membrane, cytoplasm and nuclear 
compartments of the tumour cells and cytoplasmic and nuclear compartments of 
stromal cells. Median membrane tumour cell STAT1 histoscore was 16 units (IQR: 0-
42), median cytoplasmic tumour cell STAT1 histoscore was 50 units (IQR: 15-94) 
and median nuclear tumour cell STAT1 histoscore was 8 units (IQR: 0-43).   In the 
stromal compartment, median cytoplasmic stromal cell STAT1 histoscore was 0 units 
(IQR: 0-0.33), and median nuclear stromal cell STAT1 histoscore was 0.33 units 
(IQR: 0-3.58).   
STAT1 expression in the stromal cells, membrane of tumour cells and nucleus of 
tumour cells were not associated with clinical outcome measures or survival. 
Cytoplasmic STAT1 expression when subdivided into high and low groups at the 
lower quartile (LQ), was significantly associated with time to disease recurrence (p= 
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0.001; Figure 2D). Those patients with high cytoplasmic expression had a mean time 
to disease recurrence of 3.9 years (IQR: 3.0-4.7) compared to 2 years (IQR: 1.6-2.3) 
for those with low expression. When these patients were stratified by AR expression, 
this association was lost in the group of patients expressing high levels of AR in their 
tumour (p>0.05) but was maintained in the group with low AR tumour expression 
(p=0.002).  In addition, membrane and cytoplasmic tumour cell STAT1 expression 
was inversely associated with Gleason Grade (p=0.02 and p=0.05 respectively) and 
ki67 proliferation index (p=0.024) as assessed by chi square test. 
STAT1 expression loss was not associated with levels of apoptosis in prostate 
cancer cell lines.  Having observed an association between loss of STAT1 
expression and shorter time to disease recurrence and decreased specific survival, 
the phenotypic consequence of STAT1 loss in prostate cancer cells was investigated. 
A transient STAT1 silencing model was employed in order to assess the effect of 
STAT1 loss in AR negative PC3 cells as well as AR positive LNCaP cells (Figure 
1C).   
The effect of silencing STAT1 upon cellular apoptosis in both PC3 cells and LNCaP 
cells was investigated using the cell death ELISA plus kit. Apoptosis was measure in 
PC3 and LNCaP control cells (untreated cells), siRNA control cells (cells silenced 
with scrambled siRNA) and cells silenced for STAT1 expression at 72 hours.  No 
difference in apoptotic rate of the cells was observed between any of the treatment 
groups of the PC3 cells (Figure 3A) or the LNCaP cells (Figure 3B), suggesting that 
STAT1 loss does not influence apoptotic rate in prostate cancer cell lines.  
We further explored the influence of STAT1 loss on apoptosis by studying changes of 
expression in response to STAT1 loss in a panel of genes known to be involved in 
the cellular apoptotic pathways.  Change in gene expression was assessed 72 hours 
following silencing in a panel of 96 genes.  No genes were observed to have a fold 
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change in expression of 2 or more in response to STAT1 loss. This supports our 
observation that STAT1 loss was not associated with induction of apoptosis in PC3 
cells (Figure 3C). 
Loss of STAT1 expression is associated with cell viability in prostate cancer 
cell lines.  The effect of silencing STAT1 on cell viability was measured by WST-1 
assay.  Cell viability was measured in PC3 and LNCaP control cells (untreated cells), 
siRNA control cells (cells silenced with scrambled siRNA) and cells silenced for 
STAT1 at 72 hours.  Silencing of STAT1 resulted in a significant increase in cell 
viability in PC3 cells (Control: 98.1 ± 2.3 %, siControl: 105.6 ± 4.7%, siSTAT1: 179.4 
± 9.5%)(p<0.001)(Figure 4A).  However no increase in viability was observed in 
LNCaP cells (Control: 100 ± 4.4 %, siControl: 94.9 ± 3.4%, siSTAT1: 108.8 ± 
3.4%)(P>0.05)(Figure 4B).  
Results on cell viability were confirmed by monitoring the proliferation of prostate 
cancer cells following silencing of STAT1 over a 144 hour period (6 days) using the 
xCELLigence system. Following silencing of STAT1, PC3 cells exhibited an increase 
in proliferation over mock silenced cells (Control) and scrambled siRNA (siControl) 
from 64 hours post-transfection and this increased proliferation was continuously 
observed throughout the period that the cells were monitored (Figure 4C). LNCaP 
cells silenced for STAT1 also showed an increase in proliferation around 72 hours 
post-transfection (Figure 4D), but this did not continue for the full 144 hour period.  
As we observed that loss of STAT1 influenced cell viability and proliferation of PC3 
cells, we then proceeded to assess the impact of STAT1 loss on the capability of 
PC3 cells to form clones. The number of clones formed in the silenced cells with 
siRNA STAT1 (1.4 ± 0.04) was significantly higher than those measured in the 
control (1.0 ± 0.05) and siRNA control cells (0.9 ± 0.05, p<0.001; Figure 5 A and B).    
Furthermore, the effect of STAT1 loss on migration of PC3 cells was measured using 
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a wound healing assay. Wound closure was observed at a faster rate in cells 
silenced with siRNA STAT1 cells in comparison with control cells (Figure 6A and B). 
More specifically 6h following generation of the wound, closure of the wound was 
more apparent in the PC3 cells silenced with siRNA STAT1 (wound closure 19.8% ± 
7.6 %) in comparison to control cells (wound closure 7.5% ± 4.5 %, p<0.001; Figure 
6A and 6B), this was also observed at 10 and 14 hours, with the difference in wound 
closure being most pronounced at 14 hours (wound closure of control 30.1% ± 1.8%, 
vs wound closure of siSTAT1: 76.9% ± 2.7%, p<0.001). 
 
Discussion 
Numerous transcription factors, growth factors and protein kinases have been 
associated with the progression of prostate cancer. However, the inability to 
completely control and thus eradicate the disease reveals that other unknown 
oncogenic signalling pathways may be involved in regulation of this disease. STAT1 
signalling has previously been reported to be associated with cell viability in prostate 
cancer [21, 22] and we further investigated this in patient specimens.  We observed 
that loss of STAT1 expression in patients with either localised or advanced prostate 
cancer at initial diagnosis was associated with shorter time to disease recurrence as 
well as shorter disease specific survival for patients with localised disease. Recently, 
EZH2 was demonstrated to up-regulate the STAT1 tumour suppressor action in 
DU145 and PC3 cells and therefore may be employed as a novel therapeutic agent 
in a subset of patients with low STAT1 levels [23].  In addition, Chan et al. reported 
that loss of STAT1 expression was linked with breast cancer development and 
progression, as STAT1-/- mice are highly susceptible to mammary tumour formation 
[9]. Conversely, in haematopoietic tumours such as leukaemia, high levels of STAT1 
accelerated the expression of tumours independently of the IFN signaling pathway 
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[24], moreover in human soft tissue sarcoma specimens high expression of STAT1 
was associated with reduced disease specific survival [25]. This contradictory data 
reveals that STAT1 may have different roles in different types of tumours either as a 
promoter or suppressor of the progression of the disease.  
Interestingly, the localisation of STAT3 associated with disease recurrence was 
different in localised and advanced tumours.  In localised tumours, membrane STAT3 
was associated with shorter time to disease recurrence, suggesting that classical 
pathways may be important at this stage.  However, in advanced prostate cancer, 
cytoplasmic STAT1 was associated with shorter time to disease recurrence, 
suggesting a differential role in this disease stage.  Ng et al. have shown that 
cytoplasmic STAT3 can inhibit the microtubule destabilising protein, stathmin, to 
allow stabilisation of microtubules and promote cell migration (ref).  Also, Teng et al. 
have also shown that cytoplasmic STAT3 interacts with ² PIX to modulate RAC1 
mediated cell migration and metastasis, suggesting a possible role for STAT3 in 
prostate cancer metastasis.  It is possible that a similar relationship between classical 
and alternative pathways for STAT1. 
The key role of androgens and AR, not just in early development but also in the 
progression of prostate cancer is very well characterised. In order to evaluate a 
potential regulation of AR on STAT1 expression in clinical setting, we further stratified 
localised and advanced prostate cancer patient cohorts based on expression of AR. 
When localised tumours were stratified into high and low AR-expression groups, 
associations between membrane STAT1 expression and time to disease recurrence 
was significant for both stratified groups (results not shown).  But, in patients 
diagnosed with advanced disease, the association was lost in those that were AR 
positive but remained in those with no or low AR expression.  This suggest that in 
advanced prostate cancer loss of STAT1 expression maybe a poor prognostic factor, 
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and this may be specific to a subgroup of patients with low nuclear AR expression. 
Furthermore, a study using the AR positive cell line LNCaP and the AR 
overexpressing cell line LNCaP-ARhi, demonstrated that STAT1 expression was not 
regulated in response to androgens or AR [26]. These facts combined suggest that 
STAT1 functions independently of the AR and it may be possible to use loss of 
STAT1 to identify patients with aggressive prostate cancer. Unfortunately, the 
number of patients with advanced prostate cancer in our cohort was relatively small, 
and this precluded any meaningful analysis of survival in this group; however, this 
data is interesting and further investigation in a larger cohort would be highly 
informative. 
In addition, to our observations that STAT1 expression inversely correlates with ki67 
proliferation index in the tissue specimens, we also in our cell line experiments 
observed that STAT1 plays a key role in regulating proliferation and cell viability in 
prostate cancer AR negative cells.  Induction of STAT1 loss via a siRNA approach, 
demonstrated that loss of STAT1 did not influence proliferation or cell viability in 
LNCaP AR positive cells but did in PC3 AR negative cells.  Indeed, Wee et al. 
recently reported in prostate cancer cells that Myc induced regulation of the STAT1 
pathway acted to induce tumour suppressor signalling but a similar effect was not 
observed when PI3K was employed to regulate the STAT1 pathway, again 
demonstrating the complexity of this pathway in prostate cancer [23].   Both the cell 
lines used in the current study were derived from patients with advanced disease, 
and these results are in agreement with the observations we made in the clinical 
studies where, STAT1 was associated with recurrence in patients with advanced 
prostate cancer and AR negative tumours but was not associated with recurrence in 
patients with advanced prostate cancer and AR positive tumours. In addition, it would 
be useful to study the effect of STAT1 loss in combination with AR expression in 
early prostate cancer cell lines.  In AR negative cells, we observed that the 
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clonogenic capacity of PC3 cells increase with STAT1 loss and also wounds healed 
significantly quicker.  These results again support our hypothesis that STAT1 loss 
may promote prostate cancer recurrence in a subset of patients.  It is difficult to 
convey using the wound healing assay alone, if the results observed were due to an 
increase in the motility and migration of the cells or was simply due to an increase in 
proliferation rate.  It would be interesting in future studies to probe this in more detail 
and establish if STAT1 loss only impacts on cell proliferation or if it can also increase 
the metastatic potential of the tumours by increasing cell migration and invasion.  
Additional evidence to support a role of STAT1 in progression of prostate cancer is 
provided by Roca et al. who reported that STAT1 was an important factor in the 
epithelial to mesenchymal transition, which is important for both cancer progression 
and development of metastases [27]. Wee et al., who reported that Myc can 
regulated STAT1 signalling, observed that this effect was observed in both DU145 
and PC3 cells, which are both AR negative but not in LNCaP and 22RV1 cells which 
are both AR positive [23].  They hypothesize this due to Myc sensitivity in these cells, 
however an alternative explanation could be that STAT1 was not regulated in the 
LNCaP and 22RV1 due to AR status and not Myc status [23], or conversely the 
observations made in the current study in the contrasting role of STAT1 loss in PC3 
and LNCaP cells could be due to Myc sensitivity and not AR status.     
In conclusion, the current study begins to build a body of evidence supporting the use 
of STAT1 loss as a prognostic marker for prostate cancer patients at diagnosis as 
well as in a subgroup of patients with low AR expression. Furthermore STAT1 loss 
was associated with increased proliferation in the tissue specimens and increase 
proliferation and cell viability of prostate cancer AR negative cells in our cell line 
experiments, suggesting up-regulation of STAT1 expression may serve as a novel 
therapeutic approach for prostate cancer.  However further investigations in larger 
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patient cohorts, utilising over expression of STAT1 in cell lines to compliment the 
siRNA results and in vivo mechanistic studies are required to confirm the role of 
STAT1 in prostate cancer development and progression. 
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Table 1. Clinicopathological characteristics of patients with localised prostate 
cancer (cohort 1) and advanced prostate cancer (cohort 2). 
Clinicopathological characteristics 
Localised disease Advanced disease 
Cohort 1 (M (IQR)) Cohort 2 (M (IQR)) 
Age (years) 71 (67-76) 70 (63-73) 
Gleason Grade 7 (6-8) 8 (6-9) 
PSA (ng/ml) 19 (6-78) 41 (14-43) 
Disease Recurrence (years) 2.99 (1.81-3.98) 2.6 (1.92-4.89) 
Follow Up (years) 10.5 (9.7-13.5)  
Ki67 proliferation index 1 (0-3) 1.5 (0-5.5) 




            Membrane - tumour 50 (10.8-86.7) 16 (0-42) 
            Membrane - stroma 0 0 
            Cytoplasmic - tumour 85 (50-127.5) 50 (15-94) 
            Cytoplasmic - stroma 0 0 (0-33) 
            Nuclear - tumour 35 (6.7-65) 8 (0-43) 
            Nuclear - stroma 3 (0-15) 0.33 (0-3.58) 
M=Median, IQR=intra-quartile range 
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Titles and legends for figures 
Figure1. STAT1 antibody specificity and STAT1 silencing at 72 hours (A) STAT1 
antibody on western blot detects a single band of 87 kDa in PC3 cells expressing 
STAT1 but not in PC3 silenced for STAT1. (B) demonstrates (i) that there is no non 
specific staining in the negative control, (ii) that STAT1 is expressed in prostate 
cancer tissue and (iii) that this can be blocked when the tissue is pre incubated with a 
peptide specific to the STAT1 antigen. (C) STAT1 antibody on western blot detects a 
single band of 87 kDa in both LNCaP and PC3 cells expressing STAT1 but not in 
LNCaP and PC3 cells silenced for STAT1.  This western blot confirms that silencing 
for STAT1 is maintained at 72 hours and that silencing is specific to STAT1 as no 
effect is seen when lysates are probed with STAT3 antibody. 
Figure  2. Loss of STAT1 is associated with poor prognosis in prostate cancer 
patients. (A) Representative tissue of prostate cancer specimens with low 
expression of STAT1 and high expression of STAT1. (B) Kaplan-Meier plot depicting 
that low membrane expression of STAT1 in prostate cancer patients with localised 
disease at diagnosis leads to significantly shorter time to disease recurrence (light 
grey line) compared to patients showing moderate to high expression of STAT1 
(black line).  (C) Kaplan-Meier plot depicting that low membrane expression of 
STAT1 in prostate cancer patients with localised disease at diagnosis leads to 
shorter disease specific survival time (light grey) compared to patients showing 
moderate to high expression of STAT1 (black line). (D) Kaplan-Meier plot depicting 
that low cytoplasmic expression of STAT1 in patients with advanced prostate cancer 
at initial diagnosis leads to significantly shorter time to disease recurrence (light grey 
line) compared to patients showing moderate to high expression of STAT1 (black 
line).  
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Figure 3. STAT1 silencing does not influence apoptosis in prostate cancer cell 
lines. (A) Silencing STAT1 had no significant effect on levels of apoptosis in PC3 
cells. (B) Silencing STAT1 had no significant effect on levels of apoptosis in LNCaP 
cells. (C) Silencing STAT1 does not significantly influence gene expression of 
apoptotic genes using the TLDA gene signature apoptosis array. 
Figure 4. STAT1 silencing increases AR negative prostate cancer cell line 
viability. (A) Silencing STAT1 in PC3 cells resulted in a significant increase in cell 
viability as assessed by WST-1 assay.  (B) Silencing STAT1 in LNCaP cells did not 
result in a significant change in cell viability as assessed by WST-1 assay. (C) 
Silencing STAT1 in PC3 cells resulted in an increase in cell proliferation as assessed 
by xCELLigence over 144 hour period. (D) Silencing STAT1 in LNCaP cells did not 
result in a change in cell proliferation as assessed by xCELLigence over 144 hour 
period. Graphical representation of results as mean ± sem of n=3 independent 
experiments, *p<0.05, *** p<0.0001. 
Figure 5. STAT1 silencing increases AR negative prostate cancer clonogenic 
capacity. (A) Photographic representation demonstrating that STAT1 silencing 
increases the clonogenic capability of PC3 cells. (B) Graphical representation 
demonstrating that STAT1 silencing increases the clonogenic capability of PC3 cells.  
Graphical representation of results as mean ± sem of n=3 independent experiments, 
*p<0.05, *** p<0.0001. 
Figure 6. Silencing STAT1 in PC3 cells lead to an increase in wound closure 
monitored at 0, 6, 10, 14 and 20h post wounding of the cells. (A) Photographic 
representation demonstrating that STAT1 silencing increases the wound closure of 
PC3 cells. (B) Graphical representation demonstrating that STAT1 silencing 
increases the wound closure of PC3 cells.   Graphical representation of results as 
mean ± sem of n=3 independent experiments, *p<0.05, *** p<0.0001. 






